Potent and selective DNA-PK inhibitor (IC50 = 14 nM). Selective for DNA-PK over a range of kinases including mTOR, PI 3-K, ATM and ATR. Potentiates the effects of doxorubicin (Cat. No. 2252) and etoposide (Cat. No. 1226) in vitro and etoposide in vivo. Also enhances CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency 2 to 3-fold, and decreases nonhomologous end-joining (NHEJ) frequency ~40%. Purity 99%. MW (observed): 413.49
Size
50 mg
Concentration
n/a
Applications
n/a
Other Names
8-(4-Dibenzothienyl)-2-(4-morpholinyl)-4H-1-benzopyran-4-one. KU 57788